These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 24075684)

  • 1. [IQWiG in dialog 2013: "Significance of instituting benefit assessment"].
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(6):421. PubMed ID: 24075684
    [No Abstract]   [Full Text] [Related]  

  • 2. [Legal boundaries of negative and positive lists].
    Arndt M
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):630-2. PubMed ID: 9527457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pioglitazone in evaluation by IQWiG (Institute for Quality and Cost Effectiveness in Public Health)--tunnel vision instead of broad view].
    MMW Fortschr Med; 2008 Aug; 150(32-35):56-7. PubMed ID: 19009700
    [No Abstract]   [Full Text] [Related]  

  • 4. [European drug agency and drug management].
    Barfuss W
    Leber Magen Darm; 1996 Jul; 26(4):191-2. PubMed ID: 8965600
    [No Abstract]   [Full Text] [Related]  

  • 5. [Critical aspects of current methadone treatment in Germany].
    Wagner-Servais D
    Dtsch Med Wochenschr; 2001 Mar; 126(10):275-8. PubMed ID: 11285763
    [No Abstract]   [Full Text] [Related]  

  • 6. [Increased legal liability in off-label use].
    Broglie M
    Aktuelle Urol; 2006 Nov; 37(6):417-9. PubMed ID: 17153265
    [No Abstract]   [Full Text] [Related]  

  • 7. [Negative would be welcome. The question is whose brain child this is].
    Hakimi R
    MMW Fortschr Med; 2006 Nov; 148(44):8. PubMed ID: 17632867
    [No Abstract]   [Full Text] [Related]  

  • 8. [About science and politics].
    Erdmann E
    Dtsch Med Wochenschr; 2003 Apr; 128(15):789. PubMed ID: 12690571
    [No Abstract]   [Full Text] [Related]  

  • 9. [Patient-relevant outcomes and surrogates in the early benefit assessment of drugs: first experiences].
    Kvitkina T; ten Haaf A; Reken S; McGauran N; Wieseler B
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(8-9):528-38. PubMed ID: 25523852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New institute for additional drug evaluation. Do we really need another barrier?].
    Schmidt K
    MMW Fortschr Med; 2003 Jul; 145(29-30):55-6. PubMed ID: 12958781
    [No Abstract]   [Full Text] [Related]  

  • 11. [Off-label use in psychopharmacotherapy. Letter to Federal Minister Ulla Schmidt, Pulheim, 22 January 2003].
    Fritze J
    Nervenarzt; 2003 Apr; 74(4):389; discussion 390. PubMed ID: 12800838
    [No Abstract]   [Full Text] [Related]  

  • 12. [Legal dispute about the black drug list. Irrespective of positive or negative list--I am in favor].
    Thöns M
    MMW Fortschr Med; 2006 Oct; 148(40):8. PubMed ID: 17338085
    [No Abstract]   [Full Text] [Related]  

  • 13. [Does red-green destroy phytotherapy?].
    Krankenpfl J; 2003; 41(4-6):111. PubMed ID: 12929322
    [No Abstract]   [Full Text] [Related]  

  • 14. [MSD executive calls for more transparency and expertise. 9 out of 10 innovations fail due to a too brief value assessment (interview by Wolfgang van den Bergh, Dirk Einecke and Cornelius Heyer)].
    Quodt H
    MMW Fortschr Med; 2011 Jan; 153(4):10. PubMed ID: 22165606
    [No Abstract]   [Full Text] [Related]  

  • 15. [Open letter to minister of health. Toad medicine].
    Erdmann E
    Krankenpfl J; 2003; 41(4-6):110-1. PubMed ID: 12929321
    [No Abstract]   [Full Text] [Related]  

  • 16. [Health services research: essential for allocation decisions - joint statement].
    Pfaff H; Abholz H; Glaeske G; Icks A; Klinkhammer-Schalke M; Nellessen-Martens G; Neugebauer EA; Ohmann C; Schrappe M; Selbmann HK; Stemmer R;
    Dtsch Med Wochenschr; 2011 Dec; 136(48):2496-500. PubMed ID: 21993809
    [No Abstract]   [Full Text] [Related]  

  • 17. [Off-label prescriptions. Drug use outside of established guidelines and treatment standard].
    Weissbach L; Boedefeld EA
    Urologe A; 2003 Mar; 42(3):428-32. PubMed ID: 12723544
    [No Abstract]   [Full Text] [Related]  

  • 18. [Off-label use of drugs--the legal framework].
    Koyuncu A
    Dtsch Med Wochenschr; 2012 Jul; 137(30):1519-23. PubMed ID: 22869512
    [No Abstract]   [Full Text] [Related]  

  • 19. [Negative lists and positive lists--health policy aspects].
    Huber E
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):624-7. PubMed ID: 9527455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Limited prescribing freedom by federal cost regulation?].
    Lasek R
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):633-5. PubMed ID: 9527458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.